Compare iShares MSCI South Korea ETF (EWY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs TG Therapeutics Inc — how do they compare? iShares MSCI South Korea ETF trades at $177.36 (market cap $26.25B), while TG Therapeutics Inc trades at $55 (market cap $8.16B). The key difference: iShares MSCI South Korea ETF is far larger — about 3.2× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, iShares MSCI South Korea ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 47 Days and TG Therapeutics Inc for 16 Days on average.
| EWY | TGTX | |
|---|---|---|
Market Cap | $26.25B | $8.16B |
Volume | 19,056,075 | 1,735,121 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $59.06 |
52-Week Low | $80.72 | $26.94 |
Typical Hold Time | 47 Days | 16 Days |
Enterprise Value | — | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY, the iShares MSCI South Korea ETF, trades at $177.22, down 3.54% amid broad Asian market pressure from rising oil prices and US Treasury yields. Technical indicators show a bearish trend with support at $174 and resistance at $179, while RSI levels suggest potential oversold conditions. The ETF remains heavily concentrated in Samsung and SK hynix, benefiting from AI-driven memory demand but vulnerable to semiconductor cycle volatility.
Outlook remains cautious as geopolitical tensions and high concentration risk offset strong AI fundamentals. The ETF's 148% YoY gain highlights growth potential, but investors face headwinds from global monetary tightening and oil price shocks. Key catalysts include semiconductor investment developments and US-Korea trade relations.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
